Diabetes, markers of brain pathology and cognitive function: The Age, Gene/Environment Susceptibility-Reykjavik Study

Annals of Neurology

Volumn 75, Issue 1, 2014, Pages 138-146

  Qiu, Chengxuan ^a,b   Sigurdsson, Sigurdur ^c   Zhang, Qian ^a   Jonsdottir, Maria K ^c,d   Kjartansson, Olafur ^c,e   Eiriksdottir, Gudny ^c   Garcia, Melissa E ^a   Harris, Tamara B ^a   Van Buchem, Mark A ^f   Gudnason, Vilmundur ^c,d   Launer, Lenore J ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c ICELANDIC HEART ASSOCIATION   (Iceland)

^d UNIVERSITY OF ICELAND   (Iceland)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; AGING; BRAIN; BRAIN DISEASES; COGNITION; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; ICELAND; MALE;

EID: 84894072811     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24063     Document Type: Article

References (42)

1. Launer LJ,. Diabetes: vascular or neurodegenerative: an epidemiologic perspective. Stroke 2009; 40 (3 suppl): S53-S55.
2. Ritchie K, Carrière I, Ritchie CW, et al. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 2010; 341: c3885.
3. Barnes DE, Yaffe K,. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10: 819-828.
4. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
5. Knopman DS, Penman AD, Catellier DJ, et al. Vascular risk factors and longitudinal changes on brain MRI: the ARIC study. Neurology 2011; 76: 1879-1885.
6. Qiu C, Cotch MF, Sigurdsson S, et al. Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility-Reykjavik study. Diabetes 2008; 57: 1645-1650.
7. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604-1610.
8. Korf ES, White LR, Scheltens P, Launer LJ,. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006; 29: 2268-2274.
9. Saczynski JS, Siggurdsson S, Jonsson PV, et al. Glycemic status and brain injury in older individuals: the Age Gene/Environment Susceptibility-Reykjavik study. Diabetes Care 2009; 32: 1608-1613.
10. Kalaria RN,. Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol 2009; 5: 305-306.
11. Craft S, Watson GS,. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-178.
12. Strachan MW, Reynolds RM, Marioni RE, Price JF,. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011; 7: 108-114.
13. Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology 2010; 75: 2221-2228.
14. Vernooij MW, Ikram MA, Vrooman HA, et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry 2009; 66: 545-553.
15. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77: 461-468.
16. Falvey CM, Rosano C, Simonsick EM, et al. Macro- and microstructural magnetic resonance imaging indices associated with diabetes among community-dwelling older adults. Diabetes Care 2013; 36: 677-682.
17. Harris T, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 2007; 165: 1076-1087.
18. Sigurdsson S, Aspelund T, Forsberg L, et al. Brain tissue volumes in the general population of the elderly: the AGES-Reykjavik Study. Neuroimage 2012; 59: 3862-3870.
19. Saczynski JS, Jõnsdõttir MK, Garcia M, et al. Cognitive impairment: an increasingly important complication of type 2 diabetes: the Age, Gene/ Environment Susceptibility-Reykjavik Study. Am J Epidemiol 2008; 168: 1132-1139.
20. Launer LJ, Hughes TM, White LR,. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol 2011; 70: 774-780.
21. Cukierman T, Gerstein HC, Williamson JD,. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005; 48: 2460-2469.
22. Luchsinger JA, Reitz C, Patel B, et al. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64: 570-575.
23. Roberts RO, Knopman DS, Geda YE, et al. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement 2013. doi:pii: S1552-5260(13)00013-7. 10.1016/j.jalz.2013.01.001.
24. Yeung SE, Fischer AL, Dixon RA,. Exploring effects of type 2 diabetes on cognitive functioning in older adults. Neuropsychology 2009; 23: 1-9.
25. Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012; 69: 1170-1175.
26. Spauwen PJ, Köhler S, Verhey FR, et al. Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht Aging Study. Diabetes Care 2013; 36: 1554-1561.
27. Arvanitakis Z, Leurgans SE, Barnes LL, et al. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42: 722-727.
28. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM,. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012; 11: 272-282.
29. Westover MB, Bianchi MT, Yang C, et al. Estimating cerebral microinfarct burden from autopsy samples. Neurology 2013; 80: 1365-1369.
30. Espeland MA, Bryan RN, Goveas JS, et al. Influence of type 2 diabetes on brain volume and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies. Diabetes Care 2013; 36: 90-97.
31. Manschot SM, Brands AM, van der Grond J, et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006; 55: 1106-1113.
32. Reijmer YD, Leemans A, Brundel M, et al. Disruption of the cerebral white matter network is related to slowing of information processing speed in patients with type 2 diabetes. Diabetes 2013; 62: 2112-2115.
33. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013; 36: 4036-4042.
34. Young VG, Halliday GM, Kril JJ,. Neuropathologic correlates of white matter hyperintensities. Neurology 2008; 71: 804-811.
35. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009; 8: 165-174.
36. Erten-Lyons D, Woltjer R, Kaye J, et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013; 81: 977-983.
37. Gosche KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002; 58: 1476-1482.
38. Jack CR Jr,. Alliance for aging research AD biomarkers work group: structural MRI. Neurobiol Aging 2011; 32 (suppl 1): S48-S57.
39. Erten-Lyons D, Dodge HH, Woltjer R, et al. Neuropathologic basis of age-associated brain atrophy. JAMA Neurol 2013; 70: 616-622.
40. Casserly I, Topol E,. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004; 363: 1139-1146.
41. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005; 128: 2034-2041.
42. Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 2012; 35: 787-793.